develop
novel
effect
hbv
therapeut
vaccin
construct
two
hbv
dna
immunogen
contain
sever
deliveri
method
intramuscular
im
inject
intramuscular
inject
plu
electropor
imep
intraderm
inject
plu
electropor
idep
use
murin
model
analyz
compar
immun
respons
induc
dna
immunogen
found
idep
acceler
specif
antibodi
seroconvers
produc
high
antibodi
anti
antic
antibodi
titer
immun
combin
dna
immunogen
idep
produc
strongest
multiantigen
c
specif
cellular
immun
respons
highest
specif
antibodi
level
result
indic
dna
immun
use
might
ideal
candid
abil
elicit
robust
b
cell
immun
respons
multiantigen
combin
optim
deliveri
technolog
present
studi
provid
basi
design
ration
applic
novel
hbv
dna
vaccin
hepat
b
viru
hbv
caus
acut
chronic
hepat
associ
cirrhosi
liver
cancer
although
hepat
b
vaccin
use
year
hbv
still
one
widespread
pathogen
wide
use
hbv
vaccin
subunit
vaccin
contain
fulllength
particl
express
yeast
cho
cell
hbv
vaccin
effect
mass
immun
howev
popul
produc
protect
antihbv
surfac
hb
antigen
antibodi
recent
year
variant
strain
increas
preval
drug
current
use
clinic
treatment
hepat
b
includ
interferon
nucleosid
analogu
lamivudin
due
limit
effect
drug
treatment
advers
reaction
longterm
applic
new
treatment
hbv
therapeut
hbv
vaccin
clearli
need
direct
inject
hbv
dna
immunogen
stimul
strong
longlast
humor
cellular
immun
respons
smallanim
chimpanze
model
becom
focu
research
therapeut
hbv
vaccin
recent
year
howev
appli
result
larger
popul
work
well
smallanim
model
larg
amount
dna
need
stimul
effect
immun
respons
therefor
scientist
explor
way
enhanc
immunogen
dna
vaccin
current
electropor
effect
method
dna
vaccin
deliveri
electropor
increas
antigen
ag
express
muscl
skin
direct
inject
lead
increas
immunogen
durabl
respons
reduc
effici
dose
sheep
pig
larg
anim
anoth
strategi
boost
immunogen
dna
vaccin
fuse
exogen
b
cell
epitop
viruslik
particl
vlp
vector
increas
exposur
express
express
number
viral
structur
protein
automat
assembl
viruslik
particl
carri
modifi
foreign
epitop
without
alter
particl
structur
exampl
wide
use
hbv
human
papillomaviru
hpv
vaccin
viruslik
particl
immunogen
hb
antigen
hbv
core
hbc
antigen
two
first
vlp
antigen
use
carri
foreign
epitop
previou
data
shown
express
escherichia
coli
contain
core
amino
acid
aa
aa
form
viruslik
particl
moreov
express
cho
cell
contain
aa
aa
form
stabl
secret
viruslik
particl
equival
molar
ratio
antigen
two
novel
viruslik
particl
protein
antigen
stimul
fast
effect
humor
immun
respons
anim
model
protein
vaccin
long
life
cycl
complic
purif
process
expens
moreov
effect
elicit
cell
immun
respons
usual
requir
adjuv
contrast
dna
immunogen
rel
fast
produc
inexpens
stimul
stronger
cellular
immun
respons
protein
immunogen
present
studi
construct
two
dna
plasmid
contain
particlelik
antigen
ie
contain
c
gene
sequenc
respect
describ
previous
rout
administr
two
dna
immunogen
without
electropor
compar
correspond
cellmedi
humor
immun
respons
result
demonstr
intraderm
inject
plu
electropor
combin
synergist
enhanc
effect
dna
immunogen
therefor
method
potenti
strategi
develop
novel
hbv
vaccin
therapeut
effect
construct
hbv
particlelik
dna
immunogen
plasmid
plasmid
digest
restrict
enzym
sali
bamhi
hbc
aa
pre
aa
fusion
gene
fragment
amplifi
use
pcr
plasmid
digest
sali
bamhi
gene
purifi
gel
electrophoresi
clone
sali
bamhi
site
vector
result
use
approach
amplifi
plasmid
antigen
aa
pre
antigen
aa
creat
fig
hbv
dna
immunogen
plasmid
transform
e
coli
top
strain
propag
lb
medium
contain
kanamycin
plasmid
dna
isol
verifi
use
restrict
enzym
analysi
sequenc
dna
immun
dna
plasmid
first
amplifi
e
coli
top
invitrogen
purifi
use
endofre
plasmid
giga
kit
qiagen
puriti
dna
prepar
determin
read
optic
densiti
nm
express
hbv
antigen
dna
immunogen
plasmid
confirm
cell
transient
transfect
transfect
cell
maintain
h
co
fix
methanol
express
hbv
recombin
fusion
protein
detect
use
indirect
immunofluoresc
stain
rabbit
antisera
hbcag
hbsag
level
fusion
protein
supernat
cell
lysat
harvest
h
determin
use
western
blot
analysi
anim
dna
immun
femal
balbc
mice
week
age
anim
care
center
chines
academi
medic
scienc
beij
china
randomli
assign
group
tabl
accord
institut
anim
care
use
committe
iacuc
approv
protocol
mice
immun
week
bled
week
mice
anesthet
prime
phosphatebuff
salin
pb
plasmid
dna
use
inject
tibiali
anterior
ta
muscl
intramuscular
im
l
intraderm
id
inject
lower
dorsal
side
l
gene
deliveri
use
vivo
electropor
ep
perform
previous
describ
brief
im
immun
dna
plasmid
pb
l
per
site
gdose
inject
ta
muscl
immedi
puls
electr
use
twoneedl
array
electrod
btx
needl
mm
apart
id
immun
dna
plasmid
pb
l
per
site
gdose
inject
intraderm
lower
dorsal
side
vivo
ep
appli
use
squarewav
puls
gener
btx
calip
electrod
consist
two
brass
plate
electrod
cm
ep
paramet
follow
im
vmm
ms
time
interv
ep
id
vmm
ms
time
follow
revers
electrod
vmm
ms
time
interv
ep
serum
sampl
collect
schedul
separ
serum
store
mice
sacrif
week
last
immun
spleen
mice
remov
singlecel
suspens
splenocyt
prepar
previous
describ
final
splenocyt
prepar
contain
cellsml
medium
rpmi
medium
fetal
bovin
serum
fb
penicillinstreptomycin
elisa
mous
sera
test
hbv
antigenspecif
igg
antibodi
anti
antic
respons
use
commerci
avail
enzymelink
immunosorb
assay
elisa
kit
wantai
co
accord
manufactur
instruct
optic
densiti
read
use
elisa
reader
biorad
end
titrat
titer
determin
read
last
serum
dilut
greater
negativecontrol
well
contain
normal
mous
sera
determin
igg
subclass
conduct
describ
previous
serum
sampl
immun
mice
dilut
igg
subclass
determin
use
murin
antibodyisotyp
elisa
kit
sigma
biotinyl
rat
antimous
biotinyl
rat
antimous
use
control
elispot
analysi
antigenspecif
cell
enzymelink
immunospot
elispot
assay
perform
fresh
mous
splenocyt
previous
describ
multiscreen
immobilon
p
filtrat
plate
millipor
coat
gml
purifi
rat
antimous
gamma
interferon
clone
bd
bioscienc
pb
incub
overnight
afterward
plate
wash
time
pb
plate
block
l
medium
per
well
h
peptid
use
present
studi
synthes
use
appli
biosystem
foster
citi
ca
peptid
synthes
carbon
fmoc
chemistri
synthesi
peptid
cleav
resin
protect
group
remov
peptid
purifi
use
reversephas
highperform
liquid
chromatographi
hplc
puriti
character
use
mass
spectrometri
hbv
antigenrelev
peptid
use
array
gqnlstsnp
stsnplgff
lgffpdhql
dhqldpafr
dpafranta
rantanpdw
npdwdf
npn
npnkdtwpd
hbv
antigenrelev
peptid
use
separ
two
pool
peptid
vlqagffl
ipqsldswwtsl
flggtpvcl
select
amino
acid
ag
lldyq
gmlp
glsptvwl
silspfipl
select
amino
acid
ag
hbv
core
antigenrelev
peptid
use
array
flpsdffpsv
yvnvnwglk
cltfgretv
tppatrppnapl
hiv
env
igpgrafyt
peptid
use
nonrelev
neg
control
peptid
final
concentr
gml
ad
well
l
freshli
isol
splenocyt
cellswel
medium
duplic
plate
incub
h
overnight
co
plate
wash
incub
l
biotinyl
rat
antimous
clone
bd
bioscienc
gml
pb
tween
fb
incub
overnight
addit
wash
l
alkalin
phosphataseconjug
streptavidin
complex
bd
bioscienc
ad
well
incub
h
room
temperatur
plate
wash
spot
repres
individu
cell
detect
color
reaction
use
nitroblu
nbtbcip
pierc
spotform
cell
sfc
count
result
express
number
sfc
per
input
cell
number
peptidespecif
cell
calcul
subtract
background
nopeptid
control
valu
establish
sfc
count
statist
analysi
statist
analys
perform
use
analysi
varianc
anova
studentnewmankeul
test
pearson
correl
analysi
use
ssp
differ
p
valu
consid
statist
signific
previou
studi
shown
fusion
amino
acid
hbv
may
receptorbind
domain
ctermin
domain
truncat
antigen
aa
result
express
plasmid
plasmid
form
stabl
vlp
structur
antigen
cho
cell
stimul
immun
respons
vitro
immun
moreov
fusion
amino
acid
hbv
protein
c
terminu
truncat
core
antigen
aa
result
express
plasmid
also
form
vlp
antigen
e
coli
therefor
present
studi
use
pcr
restrict
enzym
digest
clone
two
antigen
dna
vaccin
vector
pvrc
form
two
candid
dna
immunogen
fig
vitro
transient
transfect
cell
confirm
effect
express
two
fusion
antigen
assay
ifa
western
blot
analysi
use
agspecif
antibodi
fig
antigen
produc
kda
antigen
detect
two
protein
speci
molecular
mass
kda
kda
presum
reflect
nonglycosyl
glycosyl
form
result
consist
previou
report
electropor
acceler
process
seroconvers
enhanc
antibodi
respons
improv
immunogen
dna
immunogen
optim
immun
program
divid
mice
four
group
mice
group
tabl
three
immun
method
perform
im
intramuscular
inject
plu
electropor
imep
use
twoarray
needl
intraderm
inject
plu
electropor
idep
use
calip
electrod
dnaimmun
dose
id
group
g
approxim
onefifth
im
group
g
two
week
singl
doubl
hbv
dna
immun
eye
sera
mice
sampl
dilut
next
elisa
use
determin
whether
seroconvers
specif
antibodi
anti
antic
occur
seroconvers
anti
antic
antibodi
observ
singledos
inject
group
wherea
seroconvers
antibodi
observ
electropor
group
immunogen
group
seroconvers
rate
idep
group
significantli
higher
imep
group
immun
seroconvers
anti
antic
antibodi
observ
im
inject
doubleimmun
group
howev
amount
seroconvers
significantli
lower
inject
plu
electropor
group
imep
group
exhibit
highest
seroconvers
rate
group
three
immun
dna
immunogen
specif
antibodi
titer
determin
use
elisa
fig
statist
signific
differ
anti
antibodi
titer
within
group
howev
dose
requir
induc
antibodi
signific
differ
three
group
immun
mean
antibodi
titer
two
electropor
group
slightli
higher
direct
im
group
imep
group
immun
plasmid
higher
group
immun
individu
plasmid
like
due
supplementari
effect
antigen
encod
plasmid
short
result
indic
electropor
dna
immunogen
acceler
seroconvers
increas
level
antibodi
respons
moreov
intraderm
inject
plu
electropor
superior
intramuscular
inject
plu
electropor
induc
higher
antibodi
level
acceler
seroconvers
specif
antibodi
igg
subtyp
immun
sever
hbv
dna
immunogen
understand
immun
respons
group
immun
also
analyz
igg
subtyp
induc
group
blood
sampl
collect
week
last
immun
fig
igg
subtyp
antibodi
core
antigen
induc
dna
immunogen
mainli
compos
wherea
antibodi
subtyp
mixtur
slightli
larger
amount
antibodi
antibodi
subtyp
antibodi
observ
group
contain
summari
dna
immunogen
induc
immun
respons
c
antigen
howev
immun
respons
antigen
divers
slightli
bias
favor
respons
combin
two
hbv
dna
immunogen
administ
use
intraderm
electropor
synergist
enhanc
antigenspecif
cellular
immun
respons
cellular
immun
respons
critic
assess
index
effect
therapeut
vaccin
therefor
use
elispot
detect
antigenspecif
cell
spleen
cell
mice
week
receiv
three
dna
immun
peptid
librari
use
stimul
spleen
cell
describ
result
shown
fig
cell
secret
specif
respons
c
antigen
sspecif
sfc
read
highest
read
stimul
peptid
pool
significantli
higher
peptid
pool
fig
antigenspecif
sfc
read
among
group
signific
howev
number
cell
respons
c
immun
singl
plasmid
low
spleen
cell
statist
differ
interestingli
immun
plasmid
intraderm
electropor
cspecif
sfc
level
higher
spleen
cell
significantli
higher
singleplasmid
dna
immunogen
group
antigenspecif
sfc
level
higher
spleen
cell
group
plasmid
intraderm
electropor
therefor
dualplasmid
dna
immunogen
intraderm
electropor
synergist
enhanc
antigenspecif
cellular
immun
respons
tradit
vaccin
design
induc
high
titer
neutral
antibodi
howev
number
intracellular
pathogen
includ
hbv
still
caus
persist
infect
addit
neutral
antibodi
specif
cellular
immun
respons
support
antibodi
product
also
crucial
control
clearanc
infect
mani
immunolog
studi
shown
strong
cellular
immun
respons
specif
hbv
protein
includ
th
cell
cytotox
lymphocyt
ctl
detect
fig
antibodi
respons
elicit
hbv
dna
vaccin
administ
use
inject
inject
plu
ep
group
mice
micegroup
immun
use
plasmid
either
g
im
g
id
pb
three
time
interv
antisera
collect
day
postimmun
total
igg
titer
specif
hbv
antigen
determin
use
elisa
plot
describ
materi
method
symbol
repres
titer
sera
individu
mice
horizont
line
repres
mean
n
experi
repeat
least
three
time
similar
result
obtain
acut
phase
hbv
infect
recov
patient
patient
chronic
persist
hbv
infect
cellular
immun
respons
weak
undetect
anim
experi
result
show
secret
cytokin
includ
ifn
tumor
necrosi
factor
alpha
elimin
liver
hbv
infect
transgen
mice
therefor
simultan
induct
strong
humor
cellular
immun
respons
multipl
antigen
goal
develop
new
therapeut
hbv
vaccin
therapeut
hbv
vaccin
ongo
clinic
trial
use
envelop
protein
target
antigen
antigen
core
pre
polymeras
also
specif
target
immun
respons
selflimit
hepat
b
previous
report
hbvc
antigen
contain
multipl
th
ctl
epitop
hbcspecif
cellular
immun
respons
might
caus
selflimit
hbv
infect
truncat
hbc
antigenspecif
heterolog
epitop
may
use
effect
vlp
vector
significantli
enhanc
heterolog
epitop
immunogen
immun
respons
cell
addit
hb
antigen
express
cho
cell
yeast
selfassembl
spheric
vlp
use
provid
effect
protect
commerci
avail
hbv
vaccin
novel
immun
approach
base
use
combin
recombin
hbsag
hbcag
form
viruslik
particl
known
nasvac
current
develop
prevent
cure
hepat
b
vaccin
found
safe
immunogen
elicit
antihbc
antihb
seroconvers
phase
iii
trial
knowledg
prioriti
target
antigen
new
hbv
vaccin
greater
number
immunogen
cell
b
cell
epitop
protein
includ
strong
cell
epitop
aa
effect
b
cell
epitop
aa
protein
bind
site
liver
cell
aa
play
import
role
viral
attach
entri
neurath
et
al
shown
direct
immun
polypeptid
aa
protect
hbv
infect
chimpanze
addit
antibodi
produc
earlier
antibodi
cellmedi
immun
may
help
overcom
immun
unrespons
protein
certain
individu
therefor
antigen
may
play
import
role
neutral
blockad
clearanc
hbv
infect
present
studi
construct
two
kind
particlelik
structur
express
plasmid
contain
antigen
contain
hbvneutral
epitop
c
antigen
induc
respons
result
suggest
dna
immunogen
contain
gener
power
cellular
immun
respons
antibodi
inde
produc
earlier
antibodi
furthermor
respons
specif
multipl
antigen
c
bias
favor
respons
indic
product
antic
anti
antibodi
major
current
challeng
associ
use
dna
immunogen
determin
way
enhanc
respons
immun
system
recent
report
indic
vivo
electropor
significantli
enhanc
cellular
uptak
exogen
dna
express
exogen
protein
lead
aggreg
local
inflammatori
factor
thu
humor
cellular
immun
respons
induc
dna
immunogen
simultan
increas
result
effect
dose
dna
immunogen
greatli
reduc
largeanim
model
furthermor
mani
preclin
clinic
studi
indic
vivo
electropor
safe
effect
accept
method
anim
human
be
therefor
present
studi
addit
convent
direct
intramuscular
inject
appli
two
immun
method
vivo
electropor
result
indic
intraderm
inject
plu
electropor
increas
amount
specif
antibodi
seroconvers
moreov
small
dose
g
result
humor
cellular
immun
respons
robust
achiev
high
dose
g
direct
immun
interestingli
found
coreand
immun
respons
induc
separ
plasmid
weak
howev
com
fig
subtyp
analysi
hbv
antigenspecif
igg
mous
sera
expos
hbv
dna
vaccin
antigenspecif
measur
use
iggisotyp
elisa
describ
materi
method
mous
sera
collect
week
dna
immun
dilut
bar
indic
averag
optic
densiti
nm
od
igg
subtypederiv
mix
sera
group
march
guest
http
cviasmorg
bine
dna
immunogen
use
idep
induc
power
immun
respons
c
antigen
immun
dna
immunogen
contain
weak
antigen
strong
antigen
synergist
enhanc
cellular
immun
respons
therefor
specif
molecular
mechan
respons
phenomenon
deserv
studi
conclus
studi
indic
combin
dna
immunogen
immun
program
import
first
step
develop
new
effect
therapeut
hbv
vaccin
worthi
evalu
applic
larg
anim
human
also
believ
integr
molecular
adjuv
vaccin
variou
boost
approach
novel
immun
program
may
becom
best
candid
strategi
research
develop
new
therapeut
hbv
vaccin
